rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RNXT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      RenovoRx executive chairman Ramtin Agah buys $46,485 in stock
      Nov 17Investing.comRNXT
      RenovoRx Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceRNXT
      RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding Commercial ...
      Nov 6Yahoo FinanceRNXT
      RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates
      Nov 6Yahoo FinanceRNXT
      RenovoRx Q3 2026 Earnings Call Transcript
      Nov 5BenzingaRNXT
      What To Expect From RenovoRx Inc (RNXT) Q3 2026 Earnings
      Nov 4Yahoo FinanceRNXT
      RenovoRx reports case series on pancreatic cancer treatment
      Oct 1Investing.comRNXT
      RenovoRx at H.C. Wainwright conference: commercial growth builds
      Sep 14Investing.comRNXT
      RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline

      RenovoRx (NASDAQ:RNXT) will use its H. C.

      Sep 2Yahoo FinanceRNXT
      RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

      MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York P

      Sep 2Yahoo FinanceRNXT
      RenovoRx publishes pharmacokinetic data from Phase III trial
      Aug 25Investing.comRNXT
      RenovoRx regains Nasdaq minimum bid price compliance
      Aug 21Investing.comRNXT
      RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

      MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq

      Aug 21Yahoo FinanceRNXT
      RenovoRx Regains Nasdaq Compliance on Minimum Bid Price

      Detailed price information for Renovorx Inc (RNXT-Q) from The Globe and Mail including charting and trades.

      Aug 21The Globe and MailRNXT
      RenovoRx Earnings Call: Record Growth, Rising Risks

      Detailed price information for Renovorx Inc (RNXT-Q) from The Globe and Mail including charting and trades.

      Aug 21The Globe and MailRNXT

      This is the newest page. Registered accounts read further back.